Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

PBE vs BBH: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

BBH Wins Head-to-Head Institutional Verdict (0–0 across 6 Pillars · 2–1 Matrix Metrics)

BBH Overall Winner 6-Pillar Tally: PBE 0 – 0 BBH (6 Tie) Matrix Metrics: PBE 1 – 2 BBH

As of Nov 16, 2026, VanEck Biotech ETF (BBH) is the stronger overall head-to-head candidate over Invesco Biotechnology & Genome ETF (PBE) in the Tradestie Institutional Equity Comparison Engine, winning 2–1 core matrix metrics and 0–0 across our 6-pillar institutional scorecard (led by composite factor balance). PBE carries a Unified Composite Score of 53.2/100 (HOLD) at $96.22 (N/M Forward P/E, N/A operating margin), whereas BBH carries 48.1/100 (HOLD) at $249.65 (N/M Forward P/E, N/A operating margin).

  • Composite vs. Pillar Nuance: While PBE currently prints a higher short-term Unified Composite Score (53.2/100 HOLD vs. BBH 48.1/100 HOLD), BBH captures the overall institutional head-to-head verdict (2–1 matrix metrics and 0–0 across the 6 pillars) due to superior fundamental profitability (N/A vs. N/A operating margin) and revenue trajectory (N/A vs. N/A YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About PBE vs BBH
PBE NYSE Arca
Invesco Biotechnology & Genome ETF
Institutional Equity
$96.22
-1.7% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.74β · 28% Vol
Unified Composite Score
53.2 / 100 HOLD
Tech 41.0 Fund 44.0 Flow 50.0 Mom 41.1
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 44
RSI-14: 44.1 · SMA20: $100.25 · SMA50: $97.48
BBH NASDAQ Head-to-Head Winner
VanEck Biotech ETF
Institutional Equity
$249.65
-1.22% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.68β · 25% Vol
Unified Composite Score
48.1 / 100 HOLD
Tech 41.0 Fund 42.0 Flow 50.0 Mom 31.1
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (3.3% over 20 days), RSI 51
RSI-14: 51.4 · SMA20: $253.46 · SMA50: $244.21

6-Pillar Scorecard Institutional Category Breakdown (PBE 0 – 0 BBH)

Columns: Metric · PBE · BBH
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale Tie
Revenue Growth (YoY) N/A N/A
Earnings Growth (YoY) N/A N/A
TTM Revenue (USD) N/A N/A
Market Cap N/A N/A
3. Profitability & Quality Tie
Gross Margin N/A N/A
Operating Margin N/A N/A
Net Profit Margin N/A N/A
Return on Equity (ROE) N/A N/A
4. Balance Sheet & Cash Flow Tie
Cash Generation (TTM) N/A N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage N/A ROE N/A ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 23.6% (<1st %ile) 21.9% (2nd %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Institutional Equity Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: PBE (1) vs BBH (2)
Institutional Metric PBE BBH Criterion Row Edge
Market Capitalization
Scale
N/A N/A Larger Scale Tie
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
N/A N/A Higher Growth Tie
Operating Margin (TTM)
Profitability
N/A N/A Higher Margin Tie
Net Profit Margin
Profitability
N/A N/A Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
N/A N/A Higher ROE Tie
52-Week Range Position
Momentum
71% ($76–$105) 83% ($179–$264) Stronger Trend BBH
Beta / 30D Volatility
Risk Regime
0.74β · 28% Vol 0.68β · 25% Vol Lower Realized Risk BBH
Unified Institutional Score
Composite Signal
53.2 / 100 (HOLD) 48.1 / 100 (HOLD) Higher Composite PBE
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) N/A (N/A ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon BBH +3.28 pp
PBE: +0.15% · BBH: +3.43%
3M Horizon BBH +10.22 pp
PBE: +0.99% · BBH: +11.21%
6M Horizon BBH +19.08 pp
PBE: +19.69% · BBH: +38.77%
1Y Horizon BBH +9.03 pp
PBE: +23.93% · BBH: +32.96%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on PBE vs BBH. Trailing 12-month operating profitability (PBE N/A vs BBH N/A) and valuation multiples (PBE N/M vs BBH N/M Forward P/E) are benchmarked directly in Pillar 4 below.

PBE ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
BBH ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
PBE UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 23.6%
IV Percentile <1st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact PBE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
BBH UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 21.9%
IV Percentile 2nd %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BBH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
PBE Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
BBH Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ PBE vs BBH Key Questions & Quantitative Answers

As of Nov 16, 2026, VanEck Biotech ETF (BBH) is the stronger overall head-to-head candidate over Invesco Biotechnology & Genome ETF (PBE) in the Tradestie Institutional Equity Comparison Engine, winning 2–1 core matrix metrics and 0–0 across our 6-pillar institutional scorecard (led by composite factor balance). PBE carries a Unified Composite Score of 53.2/100 (HOLD) at $96.22 (N/M Forward P/E, N/A operating margin), whereas BBH carries 48.1/100 (HOLD) at $249.65 (N/M Forward P/E, N/A operating margin). Composite vs. Pillar Nuance: While PBE currently prints a higher short-term Unified Composite Score (53.2/100 HOLD vs. BBH 48.1/100 HOLD), BBH captures the overall institutional head-to-head verdict (2–1 matrix metrics and 0–0 across the 6 pillars) due to superior fundamental profitability (N/A vs. N/A operating margin) and revenue trajectory (N/A vs. N/A YoY).

PBE and BBH split Growth & Scale metrics: PBE posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with BBH at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, PBE generates N/A in USD-normalized revenue versus N/A for BBH. In operating R&D and SG&A reinvestment, PBE deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for BBH.

PBE and BBH trade at balanced relative valuation multiples. PBE trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas BBH trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PBE (N/A ROE) versus BBH (N/A ROE) capital efficiency.

In options market volatility and institutional positioning, PBE carries 23.6% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.74β · 28% Vol realized risk). By comparison, BBH carries 21.9% implied volatility (2nd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.68β · 25% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.